Efficacy and safety of Telikibart, a novel anti–IL‑4Rα monoclonal antibody, for moderate-to-severe atopic dermatitis: 52-week outcomes and prespecified subgroup analyses from a randomized, placebo‑controlled phase III trial (EADV 2026) - Jul 29, 2026 - Abstract #D3T01.3F; LB-120; Pres time: Oct 2, 2026; 03:30 PM - 03:45 PM; Location: Hall A; P3 | "Introduction Telikibart (GR1802) is a fully human monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Rα) subunit with high affinity and potent capability of inhibiting IL-4/IL-13 signaling pathway to suppress Th2-driven inflammation...(F) Prespecified subgroup analyses. *p <0.0001, †p <0.001, §p <0.01, ‡p <0.05 vs. placebo."
Clinical • Late-breaking abstract • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13 • IL4R
|
|
Shangshang Wang 1; LIMING WU 2; Yumei Li 3; Wenzhong Wu 4; Aijun Chen 5; Furen Zhang 6; Guannan Zhu 7; Jinyan Wang 8; Jianping Zhang 9; Yangfeng Ding 10; Juan Su 11; Lixia Zhang 12; Bing Liu 13; Wenlin Yang 14; Aihua Wei 15; Lunfei Liu 16; Lin Chen 17; Yan Zhang 18; Yunfeng Hu 19; Yuzhen Li 20; Qingchun Diao 21; Meiying Jiang 22; Kunpeng Bian 23; Ruzhi Zhang 24; Zaixing Wang 25; Xiaoming Liu 26; Naihui Zhou 27; Daxing Cai 28; Yan Liu 29; Xu Yao 30; Haixia Jing 31; Guangwen Yin 32; Chao Ji 33; Xiaoyan Chen 34; Rixin Chen 35; Litao Zhang 36; Bin Yin 37; Shanshan Li 38; Yi Zhao 39; Jianjun Qiao 40; Jing Yang 41; Guoqiang Zhang 42; Siping Zhang 43; Xinxiang Lv 44; Guanzhi Chen 45; Zhiming Li 46; Tiechi Lei 47; Xu Jinhua 1
|